ClinicalTrials.gg
RecruitingNCT07066397Updated Jul 23, 2025

A Phase 1 Study of FIT-CD19-CAR-T Cells in R/R B-ALL

A Phase 1 interventional study of ARM011 and Fludarabine in Acute Lymphoblastic Leukemia, sponsored by TriArm Therapeutics (Taiwan) Limited. Recruiting at 1 site in Taiwan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-07-23.

Sponsored by TriArm Therapeutics (Taiwan) Limited · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Jul 2025; still recruiting 1 year 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
12
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 20 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma with a site in Taiwan — 4 open to participants now, 8 under way, 3 of them phase 3. Precursor Cell Lymphoblastic Leukemia-Lymphoma · Taiwan.

Planned enrollment
15th of 16
12 · median 153
Started
2025
with 1 other
Phase 1
2 of 20
1 open now
Registered
18th of 20
by date

Among the 20 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma with a site in Taiwan, this one is the 15th largest by planned enrollment of the 16 interventional ones that give a count, is one of 2 that started in 2025, is one of 2 in phase 1, and was the 18th registered.

Precursor Cell Lymphoblastic Leukemia-Lymphoma

2,585 studies on the registry are indexed under Precursor Cell Lymphoblastic Leukemia-Lymphoma; 474 are open to participants now.

Browse Precursor Cell Lymphoblastic Leukemia-Lymphoma studies →

Open to participants now

4 of the 20 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma with a site in Taiwan are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Taiwan have not opened yet or have stopped. Only those recruiting at a site in Taiwan →

Who these studies take

Of the 371 Precursor Cell Lymphoblastic Leukemia-Lymphoma studies recruiting now, 96 (26%) set no upper age limit and 258 (70%) stop at 75 or younger; 248 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma with a site in Taiwan, or all of them as a file.
02

Study summary

This is a Phase 1 study to evaluate FIT-CD19-CAR-T (ARM011) safety and tolerability, anti-tumor activity, cellular kinetics, immunogenicity, and exploratory biomarkers.

Read the detailed description

This is an open-label, single arm, Phase 1 study to evaluate the safety and tolerability of FIT-CD19-CAR-T (ARM011) administered intravenously (IV) following a standard lymphodepleting (LD) chemotherapy regimen of cyclophosphamide and fludarabine in subjects with relapsed/refractory acute lymphoblastic leukemia (ALL). This dose finding study will use a 3+3 design.

03

Conditions studied

  • Acute Lymphoblastic Leukemia

Keywords

  • CAR T-Cell Therapy
  • Acute lymphoblastic leukemia
  • CD19
  • non-viral
  • fast CAR
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. Male or female subjects age ≥18 years
  2. Diagnosis of ALL
  3. to or relapsed after current standard treatment, and not suitable or unable to wait for other treatment options
  4. Disease burden: Bone marrow with evidence of disease.
  5. (ECOG) performance status ≤ 2.
  6. Adequate organ functions
  7. ≥12 weeks

Key Exclusion Criteria:

  1. Active central nervous system (CNS) involvement of ALL
  2. Burkitt's lymphoma or chronic myeloid leukemia (CML) lymphoid blast crisis
  3. Prior anti-CD19 therapy (other than blinatumomab)
  4. Subjects who have experienced Grade 3 or higher cytokine release syndrome (CRS)/neurotoxicity following blinatumomab.
  5. disease resulting in end-organ injury or requiring systemic within the last 2 years.
  6. History or presence of cardiac or CNS disorders as defined in the protocol
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
12 participants (estimated)

Study arms

  • Experimental
    ARM011 following lymphodepleting chemotherapy

    A conditioning chemotherapy regimen of fludarabine and cyclophosphamide will be administered followed by investigational treatment with ARM011

    Biological: ARM011 · Drug: Fludarabine · Drug: Cyclophosphamide

Interventions

  • BiologicalARM011

    ARM011 is an autologous, CD19 targeted CAR T-cell product developed on fast-in-time (FIT) platform-a non-viral, 2-day rapid manufacturing process

  • Administered prior to infusion of ARM011

  • Administered prior to infusion of ARM011

06

What researchers measure

Primary outcomes

  1. Incidence of adverse events [Safety and Tolerability]

    Safety and Tolerability: Proportion of subjects experiencing adverse events and dose-limiting toxicities

    Time frame: Up to 24 months after ARM011 infusion

Secondary outcomes

  1. Evaluate cellular kinetics and persistence of ARM011

    Cellular kinetics related peak (Cmax) in peripheral blood

    Time frame: Up to 24 months after ARM011 infusion

  2. Evaluate cellular kinetics and persistence of ARM011

    Area under the concentration time curve (AUC) in peripheral blood

    Time frame: Up to 24 months after ARM011 infusion

  3. Evaluate preliminary anti-tumor activity of ARM011

    Preliminary anti-tumor activity: Proportion of subjects with an objective response (including complete response or complete remission with incomplete count recovery)

    Time frame: Up to 24 months after ARM011 infusion

  4. Evaluate host immunogenicity to ARM011

    Incidence of anti-CD19-directed CAR antibodies

    Time frame: Up to 24 months after ARM011 infusion

  5. Evaluate the feasibility of administration of ARM011

    The proportion of subjects for whom a CAR T-cell product meeting specifications could be prepared, which will be computed with a corresponding 95% confidence interval (CI).

    Time frame: 24 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2025 (actual). Primary completion is estimated for Apr 2028, 32 months after the start.

Of 50 industry-sponsored phase 1 interventional studies under Precursor Cell Lymphoblastic Leukemia-Lymphoma, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 65. This study's planned 32 months is below that.

Counting every sponsor, half of 209 studies reached it within 57 months; a quarter within 35 and three quarters within 92.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 4, 2025
First posted
Jul 15, 2025
StartActual
Jul 15, 2025
Primary completionEst.
Apr 1, 2028
CompletionEst.
Apr 1, 2041
Last update
Jul 23, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 23, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07066397
Lead sponsor
TriArm Therapeutics (Taiwan) Limited
Responsible party
Sponsor
First posted
Jul 15, 2025
Start date
Jul 15, 2025
Primary completion
Apr 1, 2028 (estimated)
Completion
Apr 1, 2041 (estimated)
Last update
Jul 23, 2025

Study contacts

Reta Ruan
Contact
reta@triarm.com
+86 13641883361
Yiming Gong, MD
Contact
yiming.gong@triarmbio.com
+86 15221835460
Hosein Kouros-Mehr, MD, PhD
study director · TriArm Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion